Statement Of Cash Flows [Abstract]

OSE Immunotherapeutics - Filing #2816794

Concept 2021-01-01 to
2021-12-31
2020-01-01 to
2020-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Increase (decrease) in working capital
1 021 EUR
3 193 EUR
Adjustments for increase (decrease) in other liabilities
38,000 EUR
Adjustments for decrease (increase) in other current assets
464,000 EUR
Adjustments for increase (decrease) in employee benefit liabilities
78,000 EUR
151,000 EUR
Cash flows from (used in) financing activities [abstract]
Payments for share issue costs
0 EUR
1 203 EUR

Talk to a Data Expert

Have a question? We'll get back to you promptly.